Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 64

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 64
---
 other proprietary information by entering into confidentiality or non-disclosure
agreements with parties that have access to it, such as our development and/or commercialization partners, employees, contractors, and
consultants. We also enter into agreements that require the disclosure and assignment to us of the rights to the ideas, developments,
discoveries and inventions of our employees, advisors, research collaborators, contractors, and consultants while we employ or engage
them. However, we cannot assure you that these agreements will provide meaningful protection for our trade secrets, know-how or other
proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, know-how or other
proprietary information because these agreements can be difficult and costly to enforce or may not provide adequate remedies. Any of these
parties may breach the confidentiality agreements and willfully or unintentionally disclose our confidential information, or our competitors
might learn of the information in some other way. The disclosure to, or independent development by, a competitor of any trade secret,
know-how or other technology not protected by a patent could materially adversely affect any competitive advantage we may have over any
such competitor.

To the extent that any of our employees, advisors,
research collaborators, contractors or consultants independently develop, or use independently developed, intellectual property in connection
with any of our projects, disputes may arise as to the proprietary rights to this type of information. If a dispute arises with respect
to any proprietary right, enforcement of our rights can be costly and unpredictable, and a court may determine that the right belongs
to a third party.

Legal proceedings
or third-party claims of intellectual property infringement and other challenges, whether with or without merit, may require us to spend
substantial time and money and could prevent us from developing or commercializing Deep TMS.

The medical device industry is characterized by competing
intellectual property and a substantial amount of litigation over patent rights. In particular, our competitors in both the United States
and abroad, many of whom have substantially greater resources and have made substantial investments in competing technologies, have been
issued patents and filed patent applications with respect to their products, methods and processes and may apply for other patents in
the future. The large number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase
the risk of patent litigation.

Our commercial success depends upon our ability,
and the ability of any third party with which we may partner, to develop, manufacture, market and sell Deep TMS, and